S&P/ASX All Ords Index (ASX: XAO) shares are down 1.5% at 8,963 points on Thursday.

Meanwhile, three experts give us their views on three ASX All Ords shares on The Bull.

Let’s review. 

SKS Technologies Group Ltd (ASX: SKS)

The SKS Technologies share price is $7.89, down 1.9% today but up 155% over 12 months.

Mark Elzayed from Vestra Capital has a buy rating on this ASX 200 industrials share. 

Elzayed said: 

SKS Technologies has established a significant market footprint in electrical, fibre optic and audiovisual integration for major data centre projects.

The company generated revenue of $347.93 million in full year 2026, up 33 per cent on the prior corresponding period. Net profit after tax of $27.11 million surged 93.2 per cent. Data centre revenue of $207.7 million was up 47.6 per cent year on year.

The balance sheet is also stronger, with cash from operations increasing 30.5 per cent.

The primary catalyst for SKS is its accelerating work on hand and structural exposure to Australia’s expanding data centre market.

In my view, SKS represents a high conviction growth opportunity, supported by strong demand visibility and a substantial project pipeline.

Select Harvests Ltd (ASX: SHV)

The Select Harvests share price is $4.56, down 2.4% today and up 26% over 12 months. 

Select Harvests is the world’s No. 5 almond producer.

Elzayed has a sell rating on this ASX agriculture share.

The broker said: 

Risks include its exposure to seasonal weather volatility and intense international competition, particularly from large US and Californian almond producers.

Earnings remain exposed to agricultural yields, almond pricing and input cost volatility.

Given the stock’s relatively modest performance compared with higher growth industrial and technology opportunities, the risk-reward profile isn’t as attractive.

We would be inclined to cash in some gains after a solid share price performance since mid May.

Seek Ltd (ASX: SEK)

The Seek share price is $12.69, down 0.9% today and down 53% over 12 months. 

Blake Halligan from Gray Perry Wealth Advisers has a buy rating on this ASX 200 communications share. 

Halligan said: 

Seek operates a leading online employment marketplace, with a dominant position in Australia and established operations across Asia.

Its scalable model, strong margins and international expansion provide attractive long-term growth potential.

Despite softer job-ad volumes, fiscal year 2026 net revenue rose 10 per cent and EBITDA increased 15 per cent, demonstrating pricing power and operational resilience.

We’re forecasting earnings to grow about 9.5 per cent annually in the next two years.

An improving return on equity and a healthy dividend further support the investment case.

The post Buy, hold, sell: Select Harvests, Seek, SKS Technologies shares appeared first on The Motley Fool Australia.

More reading

• Buy alert! Expert names 2 surging ASX All Ords tech stocks to buy today
• Up 62% in a year are BHP shares now a buy, hold or sell?
• 5 things to watch on the ASX 200 on Tuesday
• This ASX consumer staples stock is tipped to rise 23%: Expert
• Experts name 3 top ASX shares to buy this week

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Sks Technologies Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

S&P/ASX All Ords Index (ASX: XAO) shares are down 1.6% to 8,961.6 points on Thursday.

Meanwhile, on The Bull, three experts give us their views on three ASX All Ords shares.

Let’s check them out. 

Saluda Medical Inc (ASX: SLD)

The Saluda Medical share price is 40 cents, down 3.7% today and down 69% over 12 months. 

Stuart Bromley from Medallion Financial Group has a buy call on this ASX All Ords healthcare share. 

Bromley said: 

Saluda makes the Evoke spinal cord stimulator, which automatically adjusts pain therapy in real time.

Results in full year 2026 were strong, in our view. Revenue of $US90.2 million was up 28 per cent on the prior corresponding period and ahead of upgraded guidance. US patient implants increased by 50 per cent in the fourth quarter of 2026.

With its newly approved CAP24 surgical paddle lead expanding the addressable US market by about 30 per cent, we believe SLD presents as an attractive buying opportunity for investors comfortable with potential share price volatility and risk.

Generation Development Group Ltd (ASX: GDG)

The Generation Development share price is $3.12, down 2.5% today and down 51% over 12 months. 

Bromley has a hold rating on this ASX 200 financial share.  

He said: 

GDG operates a portfolio of growing financial services businesses, including Generation Life, Evidentia Group and Lonsec.

Total revenue of $178.7 million in full year 2026 was up 23 per cent on the prior corresponding period.

Underlying net profit after tax of $40.7 million grew 21 per cent, supported by growth of 37 per cent in funds under management and record group net inflows of $9.7 billion.

We believe GDG’s longer term growth opportunity remains intact.

Fletcher Building Ltd (ASX: FBU)

The Fletcher Building share price is $3.04, down 2.3% today and up 9% over 12 months. 

Mark Elzayed from Vestra Capital has a sell rating on this ASX 200 industrials share. 

Elzayed said: 

The return to profitability reflected a combination of cost reductions, portfolio simplification, property sale gains and an improved performance across several core manufacturing businesses, rather than a broad based recovery in underlying construction demand.

Revenue of $NZ5.994 billion from continuing operations increased 7.3 per cent in full year 2026 when compared to the prior corresponding period.

Total net earnings attributable to shareholders reached $NZ228 million, compared to a loss of $NZ419 million in the prior year.

The return to profitability improves the balance sheet and reduces financial risk. But, in my view, a continuing recovery remains heavily dependent on building markets returning to normal in what I consider a most challenging underlying environment.

The post Buy, hold, sell: Generation Development, Fletcher Building, Saluda Medical shares appeared first on The Motley Fool Australia.

More reading

• Expert names 2 beaten-down ASX All Ords healthcare shares to buy today
• Here are the top 10 ASX 200 shares today
• Could this ASX healthcare stock really be set to rise 400%? Morgans thinks so 
• Top 3 beaten-down ASX 200 shares from August worth a second look
• The five worst-performing ASX 200 shares in August unmasked

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Generation Development Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

At the start of 2026, Ramsay Health Care Ltd (ASX: RHC) was hardly the kind of stock investors were chasing.

Fast-forward 8 months, and the picture looks very different.

Ramsay shares are up another 1.52% to $54.11 on Thursday, taking the private hospital operator to its highest level in several years.

The stock has now surged around 57% in 2026 and sits almost 80% above its 52-week low of $30.39.

It was changing hands at just $44.02 on 26 August. Since then, the share price has jumped almost 23% in a little over 2 weeks.

After years of going nowhere, Ramsay has suddenly become one of the more interesting turnaround stories on the ASX.

And I think its latest results explain a lot of the recent excitement.

The numbers are finally improving

Ramsay’s FY26 result was a pretty decent one.

Revenue came in at $18.6 billion, while underlying EBIT rose 11.8% to around $1.16 billion.

Underlying net profit after tax (NPAT) increased 19.3% to $364.1 million, or 22.9% on a constant currency basis.

Australia did much of the work, helped by higher hospital activity, better theatre utilisation, improved private health insurance pricing, and tighter cost control.

The group’s underlying EBIT margin also improved by 30 basis points to 6.2%.

Shareholders got a little extra too, with the full-year dividend rising 13.8% to 91 cents per share.

The business could look very different

Ramsay is moving ahead with plans to separate its 52.79% stake in Ramsay Santé, which owns hospitals across Europe.

Shareholders are expected to vote on the proposed demerger in November.

If the deal goes ahead, investors would be left with a simpler Ramsay business and a much clearer view of how its Australian hospitals are performing.

Ramsay is still putting money into Australia too, with the company agreeing to buy National Capital Private Hospital in Canberra for $251 million.

Management expects the acquisition to add to earnings in its first 12 months.

Would I buy Ramsay shares?

This is probably where I would be a little more careful.

At $54.11, Ramsay shares have already moved above the average TipRanks analyst price target of $50.66. The highest target is $55.69.

Director Michael Siddle also sold 1 million shares at $49 shortly after the result, in an off-market transaction worth $49 million.

Yes, I still like what I am seeing from the business, and I think the turnaround has more substance behind it.

But I wouldn’t be chasing Ramsay shares purely because they have been going up.

The post Up 57% this year. Guess which ASX 200 stock just hit a multi-year high? appeared first on The Motley Fool Australia.

More reading

• CSL led the ASX healthcare shares rebound. Can it continue?
• Top 3 ASX healthcare shares to buy after a brutal year
• Own BHP, Woodside or Coles shares? Here’s what investors should know
• 5 things to watch on the ASX 200 on Thursday
• Buy, hold, sell: Ramsay Health Care, PLS Group, Woolworths shares

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.